Wellcome Trust Case Control Consortium

Wellcome Trust Case Control Consortium
Name	Wellcome Trust Case Control Consortium
Type	Research consortium
Founded	2005
Founder	Wellcome Trust
Location	United Kingdom
Fields	Human genetics, genomics, epidemiology

Wellcome Trust Case Control Consortium is a UK-based research consortium that conducted one of the earliest large-scale genome-wide association studies. The consortium brought together researchers from academic institutions, charitable organizations, and biotechnology companies to study genetic susceptibility to common diseases. Its work influenced subsequent projects and collaborations across biomedical research institutions in Europe and North America.

Background and formation

The consortium was initiated with funding from the Wellcome Trust and incorporated investigators from institutions such as the University of Oxford, University of Cambridge, University College London, Imperial College London, and the London School of Hygiene & Tropical Medicine. Key contributors included investigators affiliated with the European Bioinformatics Institute, Medical Research Council, Addenbrooke's Hospital, and the Guy's and St Thomas' NHS Foundation Trust. The project assembled case cohorts from clinics like Royal Free Hospital, St Bartholomew's Hospital, and population controls drawn from studies such as the 1958 British birth cohort and the UK Blood Transfusion Service. It was designed in the context of preceding genetics efforts including the Human Genome Project, the International HapMap Project, and initiatives led by the National Institutes of Health and the European Union.

Major studies and methodology

The consortium's seminal publication reported genome-wide scans across multiple diseases using high-density single nucleotide polymorphism arrays supplied by companies like Affymetrix and Illumina. Study design incorporated case-control cohorts for conditions including type 1 diabetes, coronary artery disease, rheumatoid arthritis, Crohn's disease, bipolar disorder, hypertension, multiple sclerosis, Parkinson's disease, alzheimer's disease, psoriasis and asthma. Analytical methods referenced tools and resources from the Wellcome Trust Sanger Institute, the European Molecular Biology Laboratory, and statistical approaches developed in collaboration with groups at Harvard University, Massachusetts Institute of Technology, and the University of Cambridge. Quality control pipelines used genotype calling algorithms, principal component analysis for population stratification, and imputation against reference panels from the International HapMap Project and later 1000 Genomes Project. The consortium emphasized sample size, standardized phenotyping from clinics such as Moorfields Eye Hospital and biobanks including the London Multicentre Research Study, and rigorous statistical thresholds influenced by work at the Broad Institute and the Wellcome Trust Centre for Human Genetics.

Key findings and impact

The consortium identified multiple replicated loci associated with common diseases, confirming associations in genomic regions near genes characterized by groups at the Sanger Institute, the National Heart, Lung, and Blood Institute, and the European Bioinformatics Institute. Findings influenced subsequent functional genetics studies at institutions like the Max Planck Society, Karolinska Institute, Cold Spring Harbor Laboratory, and clinical translation efforts at hospitals such as Addenbrooke's Hospital and St Thomas' Hospital. The study established best-practice standards that informed projects including the International HapMap Project, 1000 Genomes Project, Genome-wide Association Studies Catalog, and initiatives led by the National Human Genome Research Institute. Its data were integrated into resources curated by the European Bioinformatics Institute, the National Center for Biotechnology Information, and the Ensembl project. Policy discussions in the Medical Research Council and debates at conferences hosted by the Royal Society and the Wellcome Trust cited the consortium's influence on study design, genetics curricula at the University of Oxford and University College London, and funding priorities at the Wellcome Trust and European Commission.

Collaborating institutions and funding

Major academic partners included the University of Oxford, University of Cambridge, University College London, Imperial College London, King's College London, University of Edinburgh, University of Glasgow, and the University of Manchester. Clinical collaborators included Guy's and St Thomas' NHS Foundation Trust, Royal Free Hospital, Addenbrooke's Hospital, St Bartholomew's Hospital, and Moorfields Eye Hospital. Bioinformatics and sequencing partnerships involved the Wellcome Trust Sanger Institute, the European Bioinformatics Institute, and commercial partners such as Affymetrix and Illumina. Funding and governance came from the Wellcome Trust with complementary support and oversight from the Medical Research Council, the National Institutes of Health, and philanthropic organizations active in biomedical research such as the Bill & Melinda Gates Foundation.

Criticisms and limitations

Critiques of the consortium's approach were raised in publications from researchers at the Broad Institute, Harvard University, Stanford University, and the Karolinska Institute concerning effect size interpretation, missing heritability debates, and generalizability across populations like those sampled in the 1000 Genomes Project and cohorts recruited through the UK Biobank. Methodological limitations discussed by statisticians at Princeton University, University of California, Berkeley, and Columbia University included reliance on common variant arrays supplied by Affymetrix and Illumina, challenges in detecting rare variants explored by groups at the Wellcome Trust Sanger Institute and the Max Planck Institute, and the requirement for larger, more diverse cohorts highlighted by investigators at the National Institutes of Health and European Molecular Biology Laboratory. Ethical and consent issues were debated in forums including the Royal Society, the Nuffield Council on Bioethics, and meetings convened by the Wellcome Trust.

Legacy and subsequent initiatives

The consortium catalyzed larger genome-wide association consortia and biobank projects such as the UK Biobank, the International HapMap Project, the 1000 Genomes Project, the Genome-wide Association Studies Catalog, and disease-specific consortia including the DIAGRAM consortium, the CARDIoGRAM consortium, and the Psychiatric Genomics Consortium. Techniques and standards influenced sequencing centers like the Wellcome Trust Sanger Institute and policy at funders such as the Wellcome Trust and the Medical Research Council. The model of multi-center collaboration echoed in programs at the National Institutes of Health, the European Commission, the Bill & Melinda Gates Foundation, and in academic networks spanning the University of Oxford, University of Cambridge, Harvard University, Broad Institute, and University College London.

Category:Genetics consortia